<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1295">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144295</url>
  </required_header>
  <id_info>
    <org_study_id>0305299</org_study_id>
    <nct_id>NCT05144295</nct_id>
  </id_info>
  <brief_title>Lubiprostone for Functional Constipation in the Under 18 Years Patients</brief_title>
  <official_title>Lubiprostone for the Treatment of Functional Constipation in the Under 18 Years Patients: A Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will enroll subjects 8 - &lt; 18 years of age, fulfilling Rome IV criteria for functional&#xD;
      constipation. They will be randomly assigned to either Lubiprostone treatment (study group),&#xD;
      or the control group (will receive either lactulose or Bisacodyl tablets). safety and&#xD;
      efficacy will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will enroll 274 subjects who will be randomly divided equally into interventional and&#xD;
      control groups.&#xD;
&#xD;
      Patients and their parents/legal guardians will be instructed to administer the doses at&#xD;
      least 5 hours apart with meals and a large volume of fluid.&#xD;
&#xD;
      The control group will receive lactulose 1 mL/kg, once or twice daily (maximum 60 mL/day or&#xD;
      Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for &lt; 12 years or 3 tab/day for &gt; 12&#xD;
      years.&#xD;
&#xD;
      Both arms will receive the treatment for 12 weeks followed by 4 weeks follow-up after the end&#xD;
      of treatment (week 16).&#xD;
&#xD;
      Patients (and their guardians) will be instructed to regularly document the number of&#xD;
      spontaneous bowel motions/week and to define their Bristol chart category for every bowel&#xD;
      motion. In addition, the participants will be encouraged to contact the trial team if any&#xD;
      adverse events appeared. This is in addition to regular visits at 0, 2, 8, 12 weeks for&#xD;
      assessment of safety (efficacy will be assessed at weeks 8, 12, and 16).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients assigned to lubiprostone will receive a dose based on their weight at the time of enrollment. patients weighing &lt;50 kg and ≥ 50 kg will be given lubiprostone at doses of 8 mg TID and 24 mg BID, respectively.&#xD;
Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and large volume of fluid.&#xD;
The control group will receive the conventional therapy (lactulose 1 mL/kg, once or twice daily (maximum 60 mL/day), or Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for &lt; 12 years or 3 tab/day for &gt; 12 years.&#xD;
Both arms will receive the treatment for 12 weeks followed by 4 weeks follow-up after the end of treatment (week 16).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome</measure>
    <time_frame>At study week 16.</time_frame>
    <description>Efficacy of lubiprostone against the control group will include the overall improvement in the constipation manifested as improved spontaneous bowel motions (SBM): defined as ≥ 1 SBM/week increase in the frequency compared with baseline, and ≥ 3 SBMs/week for at least 8 weeks, including the last 4 study weeks and the 4 weeks of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early spontanous bowel motions</measure>
    <time_frame>First 48 hours after first drug dose.</time_frame>
    <description>Number of participants who experienced first SBM within 48 hours after dose initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First dose response time</measure>
    <time_frame>1st week of treatment</time_frame>
    <description>The time between first dose of treatment and the first SBM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Spontaneous Bowel Motions/Week.</measure>
    <time_frame>At study week Week 8, 12.</time_frame>
    <description>Number of Spontaneous Bowel Motions/Week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders rate</measure>
    <time_frame>At study week Week 8, 12, 16.</time_frame>
    <description>Responders rate at week 8, 12, 16.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Clinical Efficacy</condition>
  <condition>Treatment Efficacy</condition>
  <condition>Drug Side Effect</condition>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive lubiprostone capsules (Amipriston 8 and 24mcg, or Lubicont 8 mcg)&#xD;
Patients weighing &lt;50 kg will be given lubiprostone at doses of 8 mcg/8 hours.&#xD;
Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.&#xD;
Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive the conventional therapy (one or a combination of the following):&#xD;
Lactulose &quot; Lactulose, or Duphalac syrup&quot; at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),&#xD;
Bisacodyl tablets &quot; Bisacodyl 5 mg/tablet&quot; in a dose of 2 tab/day for &lt; 12 years or 3 tab/day for &gt; 12 years, or&#xD;
Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone Pill</intervention_name>
    <description>Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.</description>
    <arm_group_label>Investigational Arm</arm_group_label>
    <other_name>Amiprostone 8 mcg caps</other_name>
    <other_name>Amiprostone 24 mcg caps</other_name>
    <other_name>Lubicont 8 mcg caps</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose Oral Liquid Product</intervention_name>
    <description>Lactulose &quot; Lactulose, or Duphalac syrup&quot; at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Lactulose OR Duphalac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisacodyl 5 MG</intervention_name>
    <description>Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for &lt; 12 years or 3 tab/day for &gt; 12 years</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Bisacodyle 5 mg tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Picosulfate</intervention_name>
    <description>Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Bisadyle 0.75% drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 8 - &lt; 18 years of age who have a confirmed diagnosis of Pediatric functional&#xD;
             constipation according to the Rome IV criteria, who give written informed consent&#xD;
             personally or from their legal guardians.&#xD;
&#xD;
          -  Discontinuation of any medication affecting gastrointestinal (GI) motility at least 2&#xD;
             weeks before starting the treatment allocation.&#xD;
&#xD;
          -  Patient's daily diary that indicates an average of &lt; 3 weekly spontaneous bowel&#xD;
             movements (SBMs), with ≥ 25% of SBMs involving at least some straining and/or a&#xD;
             5-point modified Bristol Stool Form Scale type 1 or 2.&#xD;
&#xD;
          -  Patients who completed the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. If the patient's constipation is attributed to any of the following: physical, mental,&#xD;
             or cognitive illness, inflammatory bowel disease, medication, anatomical,&#xD;
             neurological, endocrine, or metabolic factors.&#xD;
&#xD;
          2. If the patient is a candidate for or underwent abdominal surgery, or has any condition&#xD;
             other than constipation that could affect gastrointestinal motility or defecation.&#xD;
&#xD;
          3. Patients suffering from Hirschsprung's disease.&#xD;
&#xD;
          4. Patients experiencing any alarming signs e.g. unexplained significant weight loss.&#xD;
&#xD;
          5. Untreated fecal impaction at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameh A. Lashen, MD (Ph.D.)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Alexandria University - Alexandria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sameh A. Lashen, MD (Ph.D.)</last_name>
    <phone>01274117543</phone>
    <email>sameh.lashen@alexmed.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Engy S. Elkaragy, MD (Ph.D.)</last_name>
    <phone>01223193191</phone>
    <email>engy.saad@alexmed.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Sameh A. Lashen</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Lubiprostone</keyword>
  <keyword>Functional constipation</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Children</keyword>
  <keyword>Spontaneous Bowel Motions</keyword>
  <keyword>Drug safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>patient personal and identification data will not be available for sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

